David O’Neill brings extensive experience in Pharma, Biotech and seed stage investing to his role as President of FACIT. Following a role in discovery alliances at AstraZeneca, Dr. O’Neill has been involved in three start-ups that have grown to be listed on the Nasdaq. At privately held Fluorinov Pharma, he was part of a two-person management team until it was acquired by Trillium Therapeutics. He helped grow Kinomescan, a drug discovery screening business, until it was acquired by Discoverx (Eurofins). At Ambit Biosciences, he co-authored an IND and was Project Leader during early clinical development of Vanflyta, an FDA-approved precision medicine for acute myeloid leukemia. At FACIT, he has served on the Boards to Turnstone, Fusion, Triphase, Klondike and CTRL Therapeutics and led the sale of Propellon to Celgene. Dr. O’Neill holds a PhD from Western University from the Faculty of Health Sciences.